Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin Intensification for Neuroimmune and Metabolic Parameters in Coronary Heart Disease
ChiCTR2500107308Phase 4Not yet recruiting
- Sponsor
- Wuhan No.1 Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of atorvastatin in coronary arteriosclerosis (2 arms), sponsored by Wuhan No.1 Hospital. Primary endpoints: Autonomic neurotransmitter: norepinephrine, Autonomic neurotransmitter: acetylcholine and 3 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500107308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107308.